Figure 5

Survival analyses in glioma patients. Comparison of overall survival (OS) (A) between two MMP9 tissue expression groups (low and high) in glioma patients. High expression of MMP9 predicts worse outcome than low expression, but the difference is not significant; (B) between two MUC4 tissue expression groups (low and high) in glioma patients. High expression of MUC4 predicts worse outcome than low expression, but the difference is not significant. (C) MUC4-MMP9 combined high expression significantly predicts worse survival in glioma patients as assessed by the log-rank test for trend (p = 0.018). MUC4-L/MMP9-L patients have better survival than MUC4-H/MMP9-H patients as assessed by log-rank test (Mantel Cox, p = 0.023). (D) MUC4/MMP9/EGFR expression significantly predicts worse survival in glioma patients. Triple low patients (with low expression for the three markers) have better survival than double high patients (with high expression of two out of the three markers) as assessed by log-rank test (Mantel Cox, p = 0.004).